Efficacy of focal radiofrequency ablation in the treatment of low-to-intermediate risk localized prostate cancer
10.3969/j.issn.1009-8291.2025.02.010
- VernacularTitle:局灶射频消融治疗低危与中危局限性前列腺癌的疗效分析
- Author:
Shu GAO
1
;
Zhen JIANG
1
;
Jiyuan SUN
1
;
Haifeng HUANG
1
;
Qing ZHANG
1
;
Hongqian GUO
1
Author Information
1. Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210000, China
- Publication Type:Journal Article
- Keywords:
focal radiofrequency ablation;
prostate cancer;
low-to-intermediate risk;
localized;
failure-free survival rate;
urinary control;
sexual function
- From:
Journal of Modern Urology
2025;30(2):143-147
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the efficacy of focal radiofrequency ablation (RFA) in the treatment of low-to-intermediate risk localized prostate cancer and its impact on postoperative urinary control and sexual function recovery，in order to explore the feasibility of minimally invasive methods for the treatment of localized prostate cancer. Methods: Clinical data of 28 patients with low-to-intermediate risk localized prostate cancer who underwent RFA in Nanjing Drum Tower Hospital，Affiliated Hospital of Medical School during Jun.2017 and Feb.2021 were retrospectively analyzed.The 5-year failure-free survival (FFS) rate，surgery related complications，postoperative urinary control and sexual function were collected.The differences between the survival curves of patients in the low-risk and intermediate-risk subgroups were assessed with log-rank test and Breslow test. Results: All surgeries were successfully completed under local anesthesia.During the median follow-up of 43 (40-49) months，the 5-year FFS rate predicted by Kaplan-Meier method was 78.57%; 25 patients (89.29%) did not experience surgery-related complications; 27 patients (96.43%) were able to control urination; 1 patient developed new-onset sexual dysfunction.There was no significant difference in the survival curves between patients in the low-risk and intermediate-risk groups (P>0.05). Conclusion: RFA for patients with low-to-intermediate risk localized prostate cancer has good clinical efficacy，little impact on urinary control and sexual function recovery，and few postoperative complications，which can be used as one of the treatment options for these patients.
